Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer is a research paper published in Science Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 32 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30 CA082709
NIGMS NIH HHS
Grant: P20 GM121176
NCI NIH HHS
Grant: R01 CA248033
NCI NIH HHS
Grant: R01 CA280097
NCATS NIH HHS
Grant: UL1 TR002529
National Institutes of Health
Grant: 3P30CA082709-16S3
Indiana University Melvin and Bren Simon Cancer Center Support Grant
National Institutes of Health
Grant: 5UL1TR002529-02
Indiana Clinical and Translational Sciences Institute
National Institutes of Health
Grant: 5R01CA248033-04
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin Effector
FWCI
3.00
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapyresistance in prostate cancer.
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapyresistance in prostate cancer.